选择性GABA再摄取抑制剂tiagabine治疗广泛性焦虑障碍:一项安慰剂对照研究的结果。

文章的细节

引用

复制到剪贴板

波拉克MH, Roy-Byrne页,Van Ameringen M,斯奈德H, C,布朗Ondrasik J, Rickels K

选择性GABA再摄取抑制剂tiagabine治疗广泛性焦虑障碍:一项安慰剂对照研究的结果。

中国精神病学。2005年11月,66 (11):1401 - 8。

PubMed ID

16420077 (在PubMed

]

文摘

目的:探讨tiagabine的疗效和耐受性,选择性γ-氨基丁酸(GABA)再摄取抑制剂,在成人和广泛性焦虑障碍(GAD)。方法:这8周,随机、双盲、多中心、安慰剂对照研究了广泛性焦虑症患者(dsm - iv)。Tiagabine发起4毫克/天,然后灵活地给一天两次的最大剂量16毫克/天。研究药物在衰减后锥形第八周2毫克每隔一天。疗效评估包括汉密尔顿焦虑量表(HAM-A)和希恩残疾量表。不良事件、性机能、和抑郁症状的变化监测。数据收集从2003年5月到2004年1月。结果:共有266名患者(tiagabine N = 134;安慰剂,N = 132)包含在安全分析;260名患者(tiagabine N = 130; placebo N = 130) were included in efficacy analyses. Tiagabine reduced symptoms of GAD according to the observed case and mixed models repeated-measures (MMRM) analyses but not the primary last-observation-carried-forward (LOCF) analysis. At final visit, the reduction from baseline in mean HAM-A total score was 11.8 for tiagabine, compared with 10.2 for placebo (LOCF analysis, p = .27). In a post hoc MMRM analysis, a significant difference in the mean reduction in HAM-A total score over the efficacy evaluation period was found, favoring tiagabine over placebo (p < .01). Tiagabine had an early onset of effect, as shown by significant reduction from baseline in mean HAM-A total score compared with placebo at week 1 (observed cases, p < .05). Tiagabine was generally well tolerated and not associated with changes in sexual functioning or depressive status. Symptoms of a discontinuation syndrome during taper were not observed. CONCLUSION: The primary LOCF analysis was negative; however, results from the observed case and MMRM analyses suggest that tiagabine may be a useful treatment option for adult patients diagnosed with GAD. These findings warrant further evaluation in randomized clinical studies.

DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
Tiagabine	钠和chloride-dependent GABA转运体1	蛋白质	人类	是的	抑制剂	细节